Supporting this, treatment with DPP4 inhibitors confer beneficial effects on the baseline nigrostriatal dopamine degeneration and long-term motor outcomes in diabetic patients with PD and may extend its role into non-diabetic patients with PD [138]. The gene discussed is DPP4; the disease is Parkinson disease.